home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9410p.zip
/
M94A3320.TXT
< prev
next >
Wrap
Text File
|
1994-10-25
|
2KB
|
34 lines
Document 3320
DOCN M94A3320
TI Delay of emergence of ddI resistant specific mutation after long term
therapy.
DT 9412
AU Kondo M; Saito T; Hayashi T; Ito A; Nagao T; Oka S; Imai M; Kanagawa
Prefectural Institute of Health, Japan.
SO Int Conf AIDS. 1994 Aug 7-12;10(1):103 (abstract no. PA0031). Unique
Identifier : AIDSLINE ICA10/94369255
AB OBJECTIVES: To study emergence of drug resistance specific mutation
after ddI therapy and to study the effect of AZT therapy before ddI
therapy on the emergence of the mutation. METHODS: HIV-1 strains were
isolated from a patient treated with ddI and from patients switched from
AZT to ddI. The RT gene of HIV-1 isolates were amplified by PCR and
cloned to M13 vector. Five amino acid mutations in RT gene (Asp67,
Lys70, Leu74, Thr215, Lys219) associated with resistance to AZT or ddI
were analyzed. RESULTS: The ddI resistance specific mutation
(Leu74-->Val) was detected after 6 months from a patient A. But the same
mutation was not detected after more than 12 months from patients B and
C who were treated with ddI after long-term therapy with AZT.
CONCLUSIONS: These results suggest that long term therapy with AZT prior
to ddI therapy may delay the time of emergence of ddI resistance
specific mutation in patients treated with ddI.
DE Amino Acid Sequence Case Report Cloning, Molecular
Didanosine/*THERAPEUTIC USE Drug Resistance, Microbial/GENETICS Genes,
Viral Human HIV Infections/*DRUG THERAPY/*MICROBIOLOGY HIV-1/*DRUG
EFFECTS/*GENETICS/ISOLATION & PURIF *Point Mutation Polymerase Chain
Reaction Reverse Transcriptase/GENETICS Time Factors
Zidovudine/THERAPEUTIC USE MEETING ABSTRACT
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).